Union Health Minister Dr Mansukh Mandaviya, unveiled the iNNCOVACC COVID-19 vaccine yesterday in the presence of Union Minister of State for Science and Technology, Dr Jitendra Singh.
The first intranasal COVID-19 vaccine to be approved for both a heterologous booster dose and a primary 2-dose regimen is iNNCOVACC. It is created in partnership between Bharat Biotech International Limited (BBIL) and Biotechnology Industry Research Assistance (BIRAC), a PSU that falls under the Department of Biotechnology, Ministry of Science and Technology.
Dr Mandaviya, noted that more than 65 per cent of the vaccines distributed worldwide are from India. He congratulated the BBIL team and the department of Biotech for developing the world’s first nasal vaccination and said “being the world’s first intra-nasal COVID-19 vaccine, this marks a glorious tribute to the call for Atmanirbhar Bharat.”
iNCOVACC is a cost-effective covid vaccine that does not require syringes, needles, alcohol wipes, bandages, etc, saving costs related to procurement, distribution, storage, and biomedical waste disposal, that is routinely required for injectable vaccines. It makes use of a vector-based platform, which can quickly be updated with new varieties and scaled-up production within a few months.
Also Read | Digitisation is significantly boosting medical education and healthcare: Mansukh Mandaviya
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.